{"entity":{"id":"nct05841134","kind":"trial","name":"Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of tislelizumab in colorectal cancer, run by The First Affiliated Hospital of Zhengzhou University, not yet recruiting.","summary":"Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer is a phase 2, interventional study registered as NCT05841134 by The First Affiliated Hospital of Zhengzhou University, with a registry enrolment figure of 25 participants, started 2023-06-01 and due to reach its primary completion in 2024-12-31. Interventions recorded: Tislelizumab. Conditions listed: MSI-H Colorectal Cancer; Tislelizumab; Oxaliplatin; Capecitabine. Primary outcome: Percentage of Participants With Pathological Complete Response (pCR). Colorectal eligibility wording from the registry: \"Patients with colon or rectal adenocarcinoma confirmed by histology or cytology;\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05841134","url":"https://clinicaltrials.gov/study/NCT05841134"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["tislelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05841134","phase":"2","setting":"Multicenter, Single-arm, Open-label Phase II Clinical Study of Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer","sponsor":"The First Affiliated Hospital of Zhengzhou University","enrolled":25,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05841134/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}